Grant ID | RP240184 |
Awarded On | February 21, 2024 |
Title | Maximizing Anti-tumor Immunity through Simultaneous Activation of the Innate and Adaptive Immune System |
Program | Academic Research |
Award Mechanism | Individual Investigator Research Awards for Clinical Translation |
Institution/Organization | The University of Texas Southwestern Medical Center |
Principal Investigator/Program Director | Raquibul Hannan |
Cancer Sites | Kidney and Renal Pelvis |
Contracted Amount | $1,999,993 |
Lay Summary |
Immune checkpoint inhibitors (ICI) have the potential to cure patients with metastatic kidney cancer. There is a large difference in outcome between those that respond as compared to those that do not, who are unfortunately the majority. Therefore, we focused on patients that did not experience the full benefit of anti-tumor immune response from ICIs as this represents an unmet medical need. Most immunotherapy approaches to date have focused on amplifying an adaptive immune response (i.e., ICI), but more effective strategies may result from simultaneously activating the innate and adaptive immune arms as it naturally occurs. To unleash the full potential of the immune system, we propose to ... |